Genentech

Alectinib (Alecensa) is an oral kinase inhibitor used as adjuvant treatment following tumor resection and for the treatment of adults with ALK-positive metastatic non-small cell lung cancer (NSCLC). It blocks the abnormal ALK protein that drives cancer cell growth in ALK-positive tumors, helping to slow or stop the spread of cancer. It is taken by mouth as monotherapy.

Alectinib is a kinase inhibitor that targets a protein called ALK (anaplastic lymphoma kinase). In some lung cancers, changes in the ALK gene create a

Tecentriq (atezolizumab) is a PD-L1 checkpoint inhibitor from Genentech. By releasing the brake that tumours put on immune T cells, it lets the immune system attack cancer, and is used in selected lung cancers, urothelial carcinoma and other settings defined by PD-L1 testing.

T cells are immune cells that can destroy cancer, but tumours protect themselves by displaying PD-L1, a protein that binds the PD-1 switch on T cells

Ocrevus (ocrelizumab) is a CD20-directed monoclonal antibody from Genentech for relapsing forms of multiple sclerosis in adults and children aged 10 years and older, and for primary progressive MS in adults. It depletes the B cells that contribute to inflammatory damage in the brain and spinal cord.

Ocrelizumab is given by intravenous infusion and binds CD20, a protein on the surface of most B cells. Marking the cells this way triggers the body's

Omalizumab (Xolair) is a biologic medicine that binds to immunoglobulin E (IgE), the antibody that triggers allergic reactions. It is used as add-on therapy for moderate-to-severe allergic asthma, chronic spontaneous urticaria, chronic rhinosinusitis with nasal polyps, and to reduce allergic reactions from accidental food allergen exposure.

Omalizumab is an antibody that binds to free IgE, the type of antibody that drives allergic reactions. By lowering the amount of IgE circulating in th

Perjeta (pertuzumab) is a HER2/neu receptor antagonist from Genentech that blocks HER2 from pairing with other HER family receptors, shutting down a key growth signal in HER2-positive breast cancer. It is used with trastuzumab and chemotherapy in metastatic, neoadjuvant, and adjuvant settings.

Pertuzumab is a monoclonal antibody that targets the HER2 receptor on cancer cells. HER2 is a protein found in excess on some breast cancer cells, whe

Polatuzumab vedotin (Polivy) is an antibody-drug conjugate that targets CD79b, a protein found on B-cell lymphoma cells. It delivers a cancer-killing drug directly into those cells. It is used in combination with other medicines to treat certain types of non-Hodgkin lymphoma.

Polatuzumab vedotin is made of two parts: an antibody that finds lymphoma cells, and a cancer-killing drug attached to it. The antibody binds to a pro

Rituxan (rituximab) is a CD20-directed monoclonal antibody from Genentech used across blood cancers and immune diseases. It depletes B cells that carry the CD20 marker, and is used in non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, certain vasculitides, and pemphigus vulgaris.

Rituximab is a chimeric antibody given by infusion that binds CD20, a protein found on pre-B cells and mature B lymphocytes, including many B-cell can